Table 1.
Patients’ characteristics at diagnosis of AML for patients receiving palliative treatment or AML induction chemotherapy
| Palliative treatment | Induction chemotherapy | P | |
|---|---|---|---|
| N = 118 | N = 102 | ||
| Median age at diagnosis, years (range) | 75 (53–91) | 61 (25–76) | < 0.001 |
| Female patients, n (%) | 53 (44.9) | 57 (55.9) | n.s |
| Performance status, n (%) | < 0.001 | ||
| ECOG < 1 | 58 (49.2) | 75 (73.5) | |
| ECOG > 2 | 60 (51.8) | 27 (26.5) | |
| Co-morbidity index, n (%) | < 0.001 | ||
| mCCI < 1 | 62 (52.5) | 80 (78.4) | |
| mCCI > 2 | 56 (47.5) | 22 (21.6) | |
| WBC, per µL (range) | 7.6 (0.5–320) | 8,7 (0.6–331) | n.s |
| Hb, mmol/L (range) | 5.4 (2.4–8.4) | 5,6 (2.8–9.2) | |
| PLT, per µL (range) | 54 (0–297) | 62.5 (6–864) | |
| ANC, per µL (range) | 1600 (0–62,300) | 1270 (60–55,000) | |
| Percentage of blasts, % (range) | n.s | ||
| Peripheral blood | 12 (0–89) | 20 (0–96) | |
| Bone marrow | 53 (20–95) | 60 (20–98) | |
| FAB subtype, n (%) | n.s | ||
| M1/M2 | 81 (68.6) | 66 (64.7) | |
| M4/M5 | 35 (29.7) | 34 (33.3) | |
| M6 | 2 (1.7) | 2 (1.9) | |
| History of AML | n.s | ||
| de novo AML | 60 (50.8) | 58 (56.9) | |
| Antecedent MDS | 29 (24.6) | 24 (23.5) | |
| Antecedent CMML or MPN | 23 (19.5) | 14 (13.7) | |
| Therapy-related AML | 6 (5.1) | 6 (5.9) | |
| Previous therapy of MDS, CMML or MPN, n (%) | n.s | ||
| HMA | 16 (13.6) | 18 (17.6) | |
| Ruxolitinib and/ or hydroxyurea | 8 (6.8) | 4 (3.9) | |
| Lenalidomide | – | 1 (1) | |
| ASCT | – | 2 (2) | |
| ELN 2017 risk group, n (%) | 0.025 | ||
| Favorable | 16 (13.6) | 26 (25.5) | |
| Intermediate | 41 (34.7) | 30 (29.4) | |
| Unfavorable | 39 (33.1) | 44 (43.1) | |
| Not available | 22 (18.6) | 2 (2) |
AML acute myeloid leukemia, ANC absolute neutrophil count, ASCT allogeneic stem cell transplantation, CCI Charlson comorbidity index, CMML chronic myelomonocytic leukemia, FAB French-American-British classification, ECOG Eastern Cooperative oncology Groups score, ELN European LeukemiaNET classification, Hb hemoglobin level, HMA hypomethylating agent, MDS myelodysplastic syndrome, MPN myeloproliferative neoplasia, PLT platelet count, WBC white blood count